<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="824">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150431</url>
  </required_header>
  <id_info>
    <org_study_id>202109025MINA</org_study_id>
    <nct_id>NCT05150431</nct_id>
  </id_info>
  <brief_title>Optimized Acute Pain Control With Parecoxib in Uniportal Video-assisted Thoracoscopic Surgery.</brief_title>
  <official_title>Perioperative Pain-control With Parecoxib in Uniportal Video-assisted Thoracoscopic Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic pain after thoracic surgery has been a bothering problem since the era of&#xD;
      thoracotomy. The prevalence of chronic pain no matter in thoracotomy or video-assisted&#xD;
      thoracoscopic surgery is about 30 to 47%. Better acute pain control after thoracic surgery&#xD;
      has been assumed to be an effective way for prevention of chronic pain. Especially in this&#xD;
      extreme minimal invasive surgery, uniportal video-assisted thoracic surgery, more optimized&#xD;
      perioperative analgesics should be found out. In the guideline of &quot;enhanced recovery after&#xD;
      surgery&quot;, less opioid is suggested. Other than opioids, there are just few parental&#xD;
      analgesics could be used, like acetaminophen or cyclooxygenase-2(COX-2) inhibitor. In our&#xD;
      study, the investigators would like to build up a better analgesic strategy for uniportal&#xD;
      video-assisted thoracoscopic surgery with less opioid and less side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thoracic surgery has been progressed rapidly from traditional thoracotomy to triportal&#xD;
      thoracoscopy, and even uniportal thoracoscopy within past decades. Perioperative pain control&#xD;
      is always an important issue for postoperative recovery and prevention of chronic pain. The&#xD;
      acute pain is most severe in the first 2 to 4 hours after the surgery until the chest tube&#xD;
      removal. This painful sensation might postpone the ambulation time and restrain patient's&#xD;
      respiratory depth or ability to cough. Although the surgical wound is getting smaller, the&#xD;
      incidence of chronic pain is not declined as presumed. The incidence of chronic pain is&#xD;
      highly related to acute pain control. In the guideline of enhanced recovery after lung&#xD;
      surgery, multimodal analgesia is recommended. The combination of regional analgesia like&#xD;
      thoracic epidural blockade (TEB) or paravertebral nerve blockade (PVB), and medications with&#xD;
      different mechanism are beneficial for recovery. Intercostal nerve blockade is also studied&#xD;
      and popular in recent years.&#xD;
&#xD;
      However, currently there is no optimal perioperative pain control suggestion for uniportal&#xD;
      video-assisted thoracoscopic surgery (VATS). In uniportal VATS, the chest tube is the massive&#xD;
      contribution for acute pain, and which is usually removed within postoperative 24 hours. In&#xD;
      this study, the investigators would like to use the selective COX-2 inhibitor, parecoxib,&#xD;
      combined with intra-operative intercostal nerve blockade for perioperative pain control.&#xD;
      Parecoxib is relative long-acting than other currently using parental NSAID medication. The&#xD;
      primary outcome is the morphine consumption in parecoxib and placebo groups. The secondary&#xD;
      outcome is the numeric rating scale (NRS) during rest and cough, side effects, salvage&#xD;
      medications, and chronic pain incidence in 3 months. The investigators hypothesized that&#xD;
      parecoxib could effectively improve postoperative acute pain and reduce morphine consumption&#xD;
      without serious side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post-operative 2-hour morphine consumption</measure>
    <time_frame>2 hours</time_frame>
    <description>Patient-controlled analgesia will be provided to all the subjects in this study, immediately after the surgery. The investigators will record the total amounts of morphine consumption for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>post-operative 24-hour morphine consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>The investigators will record the given dosage of PCA in post-operative 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>post-operative 48-hour morphine consumption</measure>
    <time_frame>48 hours</time_frame>
    <description>The investigators will record the given dosage of PCA in post-operative 48 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>2 hours/24 hours/48 hours</time_frame>
    <description>Resting and coughing numeric rating scale will be recorded for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects caused by analgesics</measure>
    <time_frame>48 hours</time_frame>
    <description>Dizziness, nausea, vomiting, voiding difficulty, respiratory depression will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>consumption of other analgesics, besides parecoxib and morphine</measure>
    <time_frame>24 hours/48 hours</time_frame>
    <description>Additional salvage medication will be recorded and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic pain prevalence</measure>
    <time_frame>3 to 6 months</time_frame>
    <description>Telephone interview with a questionnaire will be used to follow the outcome of all subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Perioperative Care</condition>
  <condition>Chronic Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Parecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parecoxib 40mg will be administered to this group 15 minutes before the end of the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2ml normal saline will be administered to this group 15 minutes before the end of the surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parecoxib</intervention_name>
    <description>Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.</description>
    <arm_group_label>Parecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who are scheduled for uniportal video-assisted thoracoscopic surgery.&#xD;
&#xD;
          -  The American Society of Anesthesiology (ASA) score is 1 or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  moderate to severe hepatic or renal insufficiency&#xD;
&#xD;
          -  active peptic ulcer or gastrointestinal bleeding&#xD;
&#xD;
          -  allergy to salicylates&#xD;
&#xD;
          -  pregnancy or lactation period&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  accepted coronary artery bypass surgery&#xD;
&#xD;
          -  ischemic heart disease&#xD;
&#xD;
          -  peripheral vascular disease&#xD;
&#xD;
          -  cerebrovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying-Tzu Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying-Tzu Li, MD</last_name>
    <phone>00886972651903</phone>
    <email>B94401037@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>106</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying-Tzu Li, MD</last_name>
      <phone>00886972651903</phone>
      <email>B94401037@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Mineo TC, Ambrogi V. A glance at the history of uniportal video-assisted thoracic surgery. J Vis Surg. 2017 Nov 7;3:157. doi: 10.21037/jovs.2017.10.11. eCollection 2017. Review. Erratum in: J Vis Surg. 2018 May 25;4:112.</citation>
    <PMID>29302433</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Rivas D, Paradela M, Fernandez R, Delgado M, Fieira E, Mendez L, Velasco C, de la Torre M. Uniportal video-assisted thoracoscopic lobectomy: two years of experience. Ann Thorac Surg. 2013 Feb;95(2):426-32. doi: 10.1016/j.athoracsur.2012.10.070. Epub 2012 Dec 5.</citation>
    <PMID>23219257</PMID>
  </reference>
  <reference>
    <citation>Bayman EO, Parekh KR, Keech J, Selte A, Brennan TJ. A Prospective Study of Chronic Pain after Thoracic Surgery. Anesthesiology. 2017 May;126(5):938-951. doi: 10.1097/ALN.0000000000001576.</citation>
    <PMID>28248713</PMID>
  </reference>
  <reference>
    <citation>Hazelrigg SR, Cetindag IB, Fullerton J. Acute and chronic pain syndromes after thoracic surgery. Surg Clin North Am. 2002 Aug;82(4):849-65. Review.</citation>
    <PMID>12472133</PMID>
  </reference>
  <reference>
    <citation>Tong Y, Wei P, Wang S, Sun Q, Cui Y, Ning N, Chen S, He X. Characteristics of Postoperative Pain After VATS and Pain-Related Factors: The Experience in National Cancer Center of China. J Pain Res. 2020 Jul 21;13:1861-1867. doi: 10.2147/JPR.S249134. eCollection 2020. Erratum in: J Pain Res. 2020 Sep 29;13:2411. J Pain Res. 2020 Oct 12;13:2529.</citation>
    <PMID>32765060</PMID>
  </reference>
  <reference>
    <citation>Yeung JH, Gates S, Naidu BV, Wilson MJ, Gao Smith F. Paravertebral block versus thoracic epidural for patients undergoing thoracotomy. Cochrane Database Syst Rev. 2016 Feb 21;2:CD009121. doi: 10.1002/14651858.CD009121.pub2. Review.</citation>
    <PMID>26897642</PMID>
  </reference>
  <reference>
    <citation>Turhan Ö, Sivrikoz N, Sungur Z, Duman S, Özkan B, Şentürk M. Thoracic Paravertebral Block Achieves Better Pain Control Than Erector Spinae Plane Block and Intercostal Nerve Block in Thoracoscopic Surgery: A Randomized Study. J Cardiothorac Vasc Anesth. 2021 Oct;35(10):2920-2927. doi: 10.1053/j.jvca.2020.11.034. Epub 2020 Nov 20.</citation>
    <PMID>33358107</PMID>
  </reference>
  <reference>
    <citation>Maher DP, Wong W, White PF, McKenna R Jr, Rosner H, Shamloo B, Louy C, Wender R, Yumul R, Zhang V. Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesth. 2014 Jul;113 Suppl 1:i88-94. doi: 10.1093/bja/aeu192. Epub 2014 Jul 9.</citation>
    <PMID>25009195</PMID>
  </reference>
  <reference>
    <citation>Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK, Boye ME, Verburg KM. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006 Mar;104(3):518-26.</citation>
    <PMID>16508400</PMID>
  </reference>
  <reference>
    <citation>Shen H, Chen Y, Lu KZ, Chen J. Parecoxib for the prevention of shivering after general anesthesia. J Surg Res. 2015 Jul;197(1):139-44. doi: 10.1016/j.jss.2015.03.011. Epub 2015 Mar 28.</citation>
    <PMID>25908099</PMID>
  </reference>
  <reference>
    <citation>Huang JM, Lv ZT, Zhang B, Jiang WX, Nie MB. Intravenous parecoxib for early postoperative cognitive dysfunction in elderly patients: evidence from a meta-analysis. Expert Rev Clin Pharmacol. 2020 Apr;13(4):451-460. doi: 10.1080/17512433.2020.1732815. Epub 2020 Feb 28.</citation>
    <PMID>32077347</PMID>
  </reference>
  <reference>
    <citation>Bian YY, Wang LC, Qian WW, Lin J, Jin J, Peng HM, Weng XS. Role of Parecoxib Sodium in the Multimodal Analgesia after Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial. Orthop Surg. 2018 Nov;10(4):321-327. doi: 10.1111/os.12410.</citation>
    <PMID>30485685</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 31, 2021</study_first_submitted>
  <study_first_submitted_qc>December 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uniportal video-assisted thoracoscopy</keyword>
  <keyword>enhanced recovery after surgery</keyword>
  <keyword>parecoxib</keyword>
  <keyword>chronic post-operative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

